Storage and handling
Do not store above 30°C (86°F). Keep lid tightly closed and store in a dry location. USE ONLY AS DIRECTED
Do not store above 30°C (86°F). Keep lid tightly closed and store in a dry location. USE ONLY AS DIRECTED
A Palatable Supplement for the Correction of Conditions Associated with Hypothyroidism in Horses and Ponies.
KEEP OUT OF REACH OF CHILDREN
WARNING: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
For use in horses and ponies for correction of conditions associated with low circulating thyroid hormone (hypothyroidism).
Doses should be individualized and animals should be monitored daily for clinical signs of hyperthyroidism or hypersensitivity. Suggested
initial doses are 1–10 mg levothyroxine sodium (T4)/100 lb. body weight (2–20 mg/100 kg) once per day or in divided doses. Response to the administration of Thyrozine Powder should be evaluated clinically every week until an adequate maintenance dose is established. In most horses, this is usually in the range of 35 to 100 mg total daily dose of T4 (1–3 level tablespoonfuls Thyrozine Powder).
Each pound (453.6 g) contains:
Levothyroxine Sodium USP.......... 0.22% (1.0 g)
One level teaspoonful contains 12 mg of T4; one level tablespoonful contains 36 mg of T4.
Administer with caution to animals with clinically significant heart disease, hypertension or other complications for which a sharply increased metabolic rate might prove hazardous. Use in pregnant mares has not been evaluated.
Do not store above 30°C (86°F). Keep lid tightly closed and store in a dry location.
USE ONLY AS DIRECTED
1 lb (453.6 g)
10 lbs (4.5 Kg)
Trademarks are property of Clipper Distributing Company, LLC
Manufactured by:
First Priority, Inc.
Elgin, IL U.S.A.
| Class | Version | Type | Effective |
|---|---|---|---|
| LEVOTHYROXINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 97c252d3-9bb8-4530-bb44-9824dc7cf556 | Product name | 6 | 20250729 |
| 6c43b71c-35e6-4db3-ba24-c6ef42ff7003 | Product name | 3 | 20240207 |
| 890fd4bf-1a80-42b7-be1b-2d0259d5f0c8 | Product name | 5 | 20240207 |
| c8ad26bf-af73-460b-b74e-1eff16cc4f9f | Product name | 5 | 20240207 |
| 01383843-4069-43cf-aa76-dc17a6f9f8c4 | Product name | 2 | 20230123 |
| 978cca7d-a938-4791-8322-da48d90a63ef | Product name | 1 | 20230113 |
| 65f86ba3-8816-4e12-899b-18290c8de551 | Product name | 2 | 20210614 |
| f16ab90f-08c2-40be-a543-66d9827cd1f3 | Product name | 1 | 20210601 |
| 6a33ec05-2ae2-45e5-ab82-2d94b3303923 | Product name | 1 | 20190709 |
| 93355a10-1c44-4c92-a11d-7d995e0200d9 | Product name | 1 | 20190219 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 57319-455-27 | Thyrozine | 12 in 1 CASE | POWDER | 12 | 1 | |
| 57319-455-27 | Thyrozine | 453.6 g in 1 JAR | POWDER | 453.6 | 1 | |
| 57319-455-43 | Thyrozine | 4536 g in 1 PAIL | POWDER | 4536 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 57319-455 | 57319-455-27, 57319-455-43 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LEVOTHYROXINE SODIUM ANHYDROUS | 054I36CPMN | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | ONESOURCE SPECIALTY PHARMA LIMITED | ae9954a5-e196-449c-abea-ebe4afbee517 | 2026-08-12 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | MAIA Pharmaceuticals, Inc. | 4e9adc35-3aba-4a0d-9c4e-7e7ee2ffdabd | 2026-08-05 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fosun Pharma USA Inc. | 3361138a-6e6f-e8df-e063-6294a90af2de | 2025-05-05 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | ENDO USA, Inc. | 9d815416-11c9-470e-a82f-89b0bf232e12 | 2025-04-28 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | ce990712-49c1-4f66-9ee4-c770e8ec394c | 2025-04-17 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | 152d071f-d4aa-46d2-b397-61c1cabdd86d | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | f88f44d8-2f18-4155-9d78-6323d19fbafe | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Sagent Pharmaceuticals | f57e9b19-6f17-4520-80fc-511322cc56c9 | 2023-10-19 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM ANHYDROUS |
Adverse event summaries are temporarily unavailable. Other product information remains available.